NEW YORK (Reuters Health) – In patients with non-small cell lung cancer brain metastases (NSCLCBM) treated with immune-checkpoint inhibitors (ICIs) and upfront steroids, a low neutrophil-to-lymphocyte ratio (NLR) was associated with lower overall survival in a single-center retrospective analysis. “With widespread implementation of ICIs for treatment of NSCLC, many clinicians have concerns that the immunosuppressive […]
Home »
Pembrolizumab in metastatic NSCLC: Now added benefit for subpopulations
In early July, the German Institute for Quality and Efficiency in Health Care (IQWiG) conducted two early benefit assessments to investigate whether certain drug combinations with pembrolizumab have advantages in comparison with the respective appropriate comparator therapy for patients with metastatic squamous or non-squamous non-small cell lung cancer (NSCLC). Due to a contradictory presentation of […]